Valuation: Alvotech

Market Cap 1.26B 1.1B 1.02B 948M 1.79B 119B 1.82B 12.19B 4.73B 58.7B 4.73B 4.62B 205B P/E 2026 *
9.3x
P/E 2027 * 8.52x
Enterprise Value 2.36B 2.06B 1.9B 1.78B 3.35B 223B 3.41B 22.85B 8.87B 110B 8.86B 8.66B 383B EV / Sales 2026 *
3.55x
EV / Sales 2027 * 3x
Free-Float
41.72%
Yield 2026 *
-
Yield 2027 * -
1 day+7.33%
1 week-4.66%
Current month+3.57%
1 month+3.57%
3 months+11.90%
6 months-29.98%
Current year-32.16%
1 week 3.45
Extreme 3.45
3.77
1 month 2.94
Extreme 2.94
4.59
Current year 2.94
Extreme 2.94
5.58
1 year 2.94
Extreme 2.94
9.94
3 years 2.94
Extreme 2.94
18
5 years 2.94
Extreme 2.94
18
10 years 2.94
Extreme 2.94
18
Manager TitleAgeSince
Chief Executive Officer 55 01/03/2026
Director of Finance/CFO 48 10/07/2025
Chief Tech/Sci/R&D Officer - 01/01/2023
Director TitleAgeSince
Chairman 56 01/01/2019
Director/Board Member 64 01/01/2019
Director/Board Member 58 01/01/2019
Date Insider Type Main position Quantity % Market Cap.
01/04Sell

Founder

318,000 0.0963%
01/04Free

Chief Executive Officer

117,271 0.0355%
01/04Buy

Founder

318,000 0.0963%
Change 5-day change 1-year change 3-year change Capi.($)
+7.33%-4.66%-61.93%-49.57% 1.26B
+1.15%+5.94%-3.40%+2.32% 46.62B
-2.47%+10.70%+410.03%+601.46% 40.95B
-1.38%+12.78%+22.57%-14.06% 32.26B
-1.83%+3.48%+18.04%+60.26% 32.24B
-3.29%+2.85%+13.80%+30.30% 25.53B
+1.97%+12.78% - - 16.38B
-0.65%+12.93%+70.37%+122.64% 15.27B
+0.56%+5.09%+13.43%+17.88% 13.61B
-0.19%+6.23%+104.32%+96.75% 13.34B
Average +0.15%+8.17%+65.25%+96.44% 23.75B
Weighted average by Cap. -0.80%+10.25%+94.38%+137.26%

Financials

2026 *2027 *
Net sales 663M 581M 536M 500M 942M 62.73B 959M 6.43B 2.5B 30.95B 2.49B 2.44B 108B 792M 694M 640M 597M 1.13B 74.92B 1.15B 7.68B 2.98B 36.97B 2.98B 2.91B 129B
Net income 165M 144M 133M 124M 234M 15.6B 238M 1.6B 621M 7.7B 620M 606M 26.81B 134M 117M 108M 101M 190M 12.68B 194M 1.3B 504M 6.25B 504M 492M 21.79B
Net Debt 1.1B 962M 888M 828M 1.56B 104B 1.59B 10.65B 4.14B 51.28B 4.13B 4.04B 179B 1.12B 980M 904M 844M 1.59B 106B 1.62B 10.85B 4.21B 52.23B 4.21B 4.11B 182B
Logo Alvotech
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
Employees
1,279
Date Price Change Volume
25/06/26 USD 3.480 -5.95% 1,088,290
29/06/26 USD 3.720 +1.09% 690,356
26/06/26 USD 3.680 +5.75% 991,865
25/06/26 USD 3.480 -5.95% 1,088,290
24/06/26 USD 3.700 0.00% 787,083
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
3.720USD
Average target price
14.60USD
Spread / Average Target
+292.47%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALVO Stock